<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805725</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2015-04</org_study_id>
    <nct_id>NCT02805725</nct_id>
  </id_info>
  <brief_title>Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide</brief_title>
  <acronym>TARMIC</acronym>
  <official_title>Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (CP) in Patients With Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II Study From the French Sarcoma Group.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in
      patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD)
      have been determined (phase I trial).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: Multicenter Phase I trial based on a dose escalation study design (3+3 traditional
      design). Phase II: One-arm, multicenter Phase II trial based on two-stage optimal Simon's
      design.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of Trabectedin when administered in association with CP</measure>
    <time_frame>During the first cycle (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Assessment of the antitumor activity of the association of Trabectedin and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria</measure>
    <time_frame>Phase II: 6 months after the beginning of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended phase II dose (RP2D) of Trabectedin when administered in association with CP</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicities (DLT) of Trabectedin when administered in association with CP</measure>
    <time_frame>During the first cycle (28 days)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 6-month Non-progression rate (NPR) as per RECIST 1.1</measure>
    <time_frame>6-month Non-progression rate (NPR) as per RECIST</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST 1.1</measure>
    <time_frame>1-year Progression-free survival (PFS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS)</measure>
    <time_frame>1-year Overall Survival (OS) as per RECIST</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as Area Under Curve for CP</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as Area Under Curve for Trabectedin</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as half-life for CP</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as half-life for Trabectedin</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as concentration peak for CP</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: PK measurements expressed as concentration peak for Trabectedin</measure>
    <time_frame>Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Predictive biomarkers analysis (cytokines levels)</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Predictive biomarkers analysis (VEGF and TPS-1 levels)</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Predictive biomarkers analysis (lymphocytes levels)</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&amp;E))</measure>
    <time_frame>before treatment initiation and Day 28 cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC)</measure>
    <time_frame>before treatment initiation and Day 28 cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST V1.1</measure>
    <time_frame>1-year Progression-free survival (PFS) as per RECIST</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS)</measure>
    <time_frame>1-year Overall Survival (OS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Toxicity graded using the common toxicity criteria from the NCI v4.0</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II (optional): Predictive biomarkers analysis (cytokines levels)</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II (optional): Predictive biomarkers analysis (VEGF and TPS-1 levels)</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II (optional): Predictive biomarkers analysis (lymphocyte levels</measure>
    <time_frame>Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>27. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&amp;E))</measure>
    <time_frame>before treatment initiation and Day 28 cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC)</measure>
    <time_frame>before treatment initiation and Day 28 cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Soft-tissue Sarcomas</condition>
  <arm_group>
    <arm_group_label>Phase 1: Trabectedin + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Trabectedin + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 1: Trabectedin</intervention_name>
    <description>A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Patients will be allocated 4 doses of Trabectedin following a 3 + 3 design:</description>
    <arm_group_label>Phase 1: Trabectedin + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 2: Trabectedin</intervention_name>
    <description>All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial.</description>
    <arm_group_label>Phase 2: Trabectedin + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 1: Cyclophosphamide</intervention_name>
    <description>A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.</description>
    <arm_group_label>Phase 1: Trabectedin + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 2: Cyclophosphamide</intervention_name>
    <description>All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.</description>
    <arm_group_label>Phase 2: Trabectedin + Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with soft-tissue sarcoma histologically confirmed by central review

          2. Metastatic or unresectable locally advanced disease,

          3. Age ≥ 18 years,

          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2,

          5. Life expectancy &gt; 3 months,

          6. Measurable disease according to RECIST v1.1 outside any previously irradiated field,

          7. For patients included in phase II study, progressive disease according to RECIST v1.1
             criteria diagnosed on the basis of two CT scan or MRI obtained at an interval less
             than 6 months in the period of 12 months prior to inclusion and confirmed by central
             review,

          8. Previous use of Anthracyclines,

          9. Have provided tissue from an archival tissue sample,

         10. At least three weeks since last chemotherapy, immunotherapy or any other
             pharmacological treatment and/or radiotherapy,

         11. Adequate hematological, renal, metabolic and hepatic function:

               1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell [RBC]
                  transfusion, if clinically indicated); absolute neutrophil count (ANC) ≥ 1.5 x
                  10^9/l, and platelet count ≥ 100 x 10^9/l

               2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST)&lt; or = 2.5 x
                  upper limit of normality (ULN) ( &lt; or = 5 in case of extensive liver involvement)
                  and alkaline phosphatase (AP) &lt; or = 2.5 x ULN

               3. Total bilirubin &lt; or = ULN.

               4. Albumin ≥ 25 g/l

               5. Serum Creatinine &lt; or =1.5 x ULN or calculated creatinine clearance (CrCl) ≥ 30
                  ml/min (according to Cockroft formula).

               6. Creatine Phosphokinase (CPK) &lt; or = 2.5 x ULN

         12. Women of childbearing potential must have a negative serum pregnancy test before study
             entry. Both women and men must agree to use a medically acceptable method of
             contraception throughout the treatment period and for six months after discontinuation
             of treatment. Acceptable methods of contraception include intrauterine device (IUD),
             oral contraceptive, subdermal implant and double barrier,

         13. No prior or concurrent malignant disease diagnosed or treated in the last 2 years
             except for adequately treated in situ carcinoma of the cervix, basal or squamous skin
             cell carcinoma, or in situ transitional bladder cell carcinoma,

         14. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment
             (excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2)
             according to the National Cancer Institute Common Terminology Criteria for Adverse
             Events (NCI-CTCAE, version 4.0),

         15. Patients with a French social security in compliance with the Law relating to
             biomedical research (Article 1121-11 of French Public Health Code),

         16. Voluntarily signed and dated written informed consent prior to any study specific
             procedure.

        Exclusion Criteria:

          1. Previous treatment with Trabectedin,

          2. Currently active bacterial or fungus infection (&gt; grade 2 CTC [CTCAE] HIV1, HIV2,
             hepatitis B or hepatitis C infections,

          3. History of chronic alcohol use and/or cirrhosis,

          4. The following unstable cardiac conditions are not allowed:

               -  Congestive heart failure

               -  Angina pectoris

               -  Myocardial infarction within 1 year before registration

               -  Uncontrolled arterial hypertension defined as blood pressure ≥ 150/100 mmHg
                  despite optimal medical therapy

               -  Arrhythmias clinically significant

          5. Patients unable to receive corticotherapy,

          6. Known central nervous system malignancy (CNS),

          7. Men or women of childbearing potential who are not using an effective method of
             contraception as previously described; women who are pregnant or breast feeding,

          8. Participation to a study involving a medical or therapeutic intervention in the last
             30 days,

          9. Previous enrolment in the present study,

         10. Patient unable to follow and comply with the study procedures because of any
             geographical, social or psychological reasons,

         11. Known hypersensitivity to any involved study drug or any of its formulation
             components.

         12. Recent vaccination (in the last 2 weeks before inclusion) for yellow fever.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ITALIANO Antoine, MD, PhD</last_name>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MATHOULIN-PELISSIER Simone, MD,PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah DUMONT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sarah DUMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumor</keyword>
  <keyword>Advanced pretreated soft tissue sarcomas</keyword>
  <keyword>Phase I/II trial</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>PK study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

